Ampa Unveils Portable FDA-Cleared Brain Stimulation System Across the Nation After Successful $8.5 Million Funding

Ampa Launches Nationwide with Ampa One

In a significant advancement for mental health treatment, Ampa announces the nationwide rollout of its FDA-cleared brain stimulation device, the Ampa One. This comes only four months after the company emerged from stealth mode, having secured a remarkable $8.5 million in oversubscribed funding, primarily led by Nexus NeuroTech Ventures. This launch is poised to change how patients receive mental health care across the United States.

The Ampa One system is a portable, camera-guided Transcranial Magnetic Stimulation (TMS) device. Designed with both simplicity and portability in mind, it caters to modern clinic needs, making advanced brain stimulation more accessible than ever. As mental health issues affect millions, access to effective treatment options becomes increasingly critical.

Dr. Don Vaughn, a neuroscientist and the CEO of Ampa, emphasized the urgent need for new treatment options in today's world, characterized by rising depression rates even as medication usage increases. He stated, "People deserve new options, and the Ampa One was built to provide clinicians with a practical, portable, and affordable tool that can help expand patient access to lifesaving technology."

In conjunction with its launch, Ampa is in the process of developing the Ampa One Day protocol, a groundbreaking treatment that reduces a traditional multi-week timeline into a single day of TMS treatment. This innovative approach could redefine rapid-acting treatments for mental health, potentially setting a new benchmark in the field.

Dr. Tobias Marton, Chief Medical Officer at Mindful Health Solutions, speaks highly of the Ampa One, stating, "Ampa represents a revolution in TMS therapy. The portability and intuitive design are impressive, and the confirmed target engagement truly redefines how and where TMS can be delivered. Ampa facilitates broader access and improved outcomes through scalable next-generation protocols."

The response from investors has also been robust, demonstrating confidence in Ampa's vision to revolutionize the mental health industry. The recent Pre-A funding round included significant backing from Nexus NeuroTech Ventures, committing $2 million, alongside Satori Capital, Morningside Ventures, and Continuum Health Ventures, among others. Individual investors include physicians and other stakeholders who recognize the potential for transformative change in mental health treatment.

John Propst, Principal at Nexus NeuroTech Ventures, reflects on the importance of Ampa's dual focus: "Ampa is setting a new standard for what neuromodulation looks like in clinical practice. We are proud to support a company that delivers both scientific innovation and operational scalability simultaneously."

The launch of the Ampa One into commercial distribution signals a growing momentum in the realm of non-invasive brain stimulation. With significant numbers of individuals suffering from depression, anxiety, and related conditions, Ampa's mission aims to shift the paradigm from viewing remission as an exception to making it the standard outcome.

About Ampa

Ampa is a neurotechnology firm dedicated to leveraging breakthroughs in neuroscience to create practical tools that can significantly improve mental health recovery. With its FDA-cleared Ampa One system and the upcoming Ampa One Day protocol, the company’s guiding mission is to achieve one billion remissions from mental and neurological disorders. For more information, visit ampahealth.com.